Last reviewed · How we verify
HDARAC
HDARAC, marketed by Johann Wolfgang Goethe University Hospital, is a small molecule with a unique mechanism of action that interacts with specific biological pathways. The key composition patent for HDARAC is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | HDARAC |
|---|---|
| Sponsor | Johann Wolfgang Goethe University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (PHASE4)
- German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDARAC CI brief — competitive landscape report
- HDARAC updates RSS · CI watch RSS
- Johann Wolfgang Goethe University Hospital portfolio CI